1
Pankai J Pasricha, Anthony N Kalloo: Method for treating gastrointestinal muscle disorders and other smooth muscle dysfunction. August 1, 1995: US05437291 (228 worldwide citation)

Direct injection of sphincteric botulinum toxin is disclosed as an effective, safe and simple method of treatment for disorders of gastrointestinal muscle or smooth muscles elsewhere in the body, with results that appear to be sustained for several months. Muscle disorders which are suitable for suc ...


2
James Aggen, John H Griffin, Mathai Mammen, Daniel Marquess, Edmund J Moran, David Oare: Muscarinic receptor antagonists. Theravance, Jeffrey A Hagenah, Joyce G Cohen, February 17, 2004: US06693202 (123 worldwide citation)

Disclosed are multibinding compounds which are muscarinic receptor antagonists. The multibinding compounds of this invention containing from 2 to 10 ligands covalently attached to one or more linkers. Each ligand is, independently of each other, a muscarinic receptor antagonist or an allosteric modu ...


3
Pankaj J Pasricha, Anthony N Kalloo: Device for treating gastrointestinal muscle disorders and other smooth muscle dysfunction. The Johns Hopkins University, Banner & Witcoff, October 7, 1997: US05674205 (100 worldwide citation)

Direct injection of sphincteric botulinum toxin is disclosed as an effective, safe and simple method of treatment for disorders of gastrointestinal muscle or smooth muscles elsewhere in the body, with results that appear to be sustained for several months. Muscle disorders which are suitable for suc ...


4
Nicholas D Cosford, Jean Michel Vernier: Substituted pyridines useful as modulators of acethylcholine receptors. SIBIA Neurosciences, Stephen E Gray Care Ware & Freidenrich Reiter, December 22, 1998: US05852041 (91 worldwide citation)

In accordance with the present invention, there provided a class of pyridine compounds which are modulators of acetylcholine receptors. The compounds of the invention displace acetylcholine receptor ligands from their binding sites. Invention compounds may act as agonists, partial agonists, antagoni ...


5
Paul Edward Aldrich, Argyrios Georgios Arvanitis, Robert Scott Cheeseman, Robert John Chorvat, Thomas Eugene Christos, Paul Joseph Gilligan, Dimitri Emil Grigoriadis, Carl Nicholas Hodge, Paul John Krenitsky, Everett Latham Scholfield, Sang William Tam, Zelda Rakowitz Wasserman: 1N-alkyl-n-arylpyrimidinamines and derivatives thereof. DuPont Pharmaceuticals Company, Robert W Black, Kenneth B Rubin, Kalim S Fuzail, January 29, 2002: US06342503 (65 worldwide citation)

The present invention provides novel compounds, compounds and pharmaceutical compositions thereof, and methods of using same in the treatment of affective disorders, anxiety, depression, post-traumatic stress disorders, eating disorders, supranuclear palsy, irritable bowel syndrome, immune suppressi ...


6
Stanley M Crain, Ke fei Shen, Gerald M Fleischner: Method and composition for treating irritable bowel syndrome using low doses of opioid receptor antagonists. Albert Einstein College of Medicine of Yeshiva University, Amster Rothstein & Ebenstein, February 27, 2001: US06194382 (64 worldwide citation)

This invention relates to a method for eating a subject with irritable bowel syndrome (“IBS”) which comprises long-term administration of an opioid receptor antagonist at an appropriately low dose which will selectively antagonize excitatory opioid receptor functions, but not inhibitory opioid recep ...


7
Thomas J Borody: Treatment of non-inflammatory and non-infectious bowel disorders. James Ray & Associates, May 21, 1996: US05519014 (63 worldwide citation)

A medicine for treating non-inflammatory and non-infectious bowel disorders, such as irritable bowel syndrome, constipation, non-ulcer dyspepsia, gastro-oesophageal reflux with or without oesophagitis, and diverticular disease, comprising a salicylic acid derivative, such as any one of sulfasalazine ...


8
Mary E Abreu, Waclaw Rzeszotarski, Donald J Kyle, Roger N Hiner, Richard L Elliott: Corticotropin-releasing factor antagonism compounds. Nova Pharmaceutical Corporation, Vincent L Fabiano, November 5, 1991: US05063245 (62 worldwide citation)

The present invention relates to a method of producing corticotropin-releasing factor (CRF) antagonist activity and thus provides a method of treating a wide range of stress-related disorders, including affective illnesses, such as depression and anxiety, as well as irritable bowel syndrome, anorexi ...


9
Stanley M Crain, Ke fei Shen, Gerald M Fleischner: Method and composition for treating irritable bowel syndrome using low doses of opioid receptor antagonists. Albert Einstein College of Medicine of Yeshiva University, Amster Rothstein & Ebenstein, May 28, 2002: US06395705 (61 worldwide citation)

This invention relates to a method for treating a subject with irritable bowel syndrome (“IBS”) which comprises long-term administration of an opioid receptor antagonist at an appropriately low dose which will selectively antagonize excitatory opioid receptor functions, but not inhibitory opioid rec ...


10
Henry C Lin, Mark Pimentel: Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth. Cedars Sinai Medical Center, Pillsbury Winthrop, March 1, 2005: US06861053 (59 worldwide citation)

Disclosed is a method of diagnosing irritable bowel syndrome, fibromyalgia, chronic fatigue syndrome, depression, attention deficit/hyperactivity disorder, autoimmune diseases, such as multiple sclerosis and systemic lupus erythematosus, or Crohn's disease, which involves detecting the presence of s ...



Click the thumbnails below to visualize the patent trend.